The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia
Abstract
OBJECTIVE: Postmortem studies and a positron emission tomography (PET) study have suggested that there is a disturbance of central D(1) dopamine receptor function in schizophrenia. The objective of the present PET study was to compare D(1) receptor binding in first-admission, neuroleptic-naive patients with schizophrenia and in healthy subjects. METHOD: Ten healthy comparison subjects and 10 neuroleptic-naive patients with schizophrenia (diagnosed according to DSM-III-R) were examined twice by PET using (11)C-labeled SCH 23390 ([(11)C]SCH 23390) with high and low specific radioactivity, respectively. The binding potential, receptor density (B(max)), and affinity (K(d)) were determined for the caudate nucleus, the putamen, and several neocortical regions during both PET examinations. Scatchard plots from the two measurements were used to calculate regional D(1) B(max) and K(d). The regional binding values were tested for hemispheric asymmetry and for correlation to clinical symptoms measured by the Brief Psychiatric Rating Scale (BPRS). RESULTS: [(11)C]SCH 23390 binding to D(1) receptors did not differ significantly between subjects with schizophrenia and healthy subjects in any of the brain regions or for any of the binding measures studied. Asymmetry of the regional binding values did not differ significantly between the two groups. Scores on the BPRS negative symptom subscale correlated significantly with the B(max) in the right frontal cortex. CONCLUSIONS: These results do not replicate previous postmortem and PET findings of altered central dopamine D(1) receptor binding in schizophrenia. The finding of a positive correlation between frontal D(1) binding and scores on the negative symptom subscale of the BPRS is contrary to a previously reported finding of a negative correlation. These discrepancies motivate further studies using D(1) ligands with higher signals for cortical regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Human brain dopamine receptors in children and aging adults
Seeman, P., Bzowej, N. H., Guan, H. ‐., Bergeron, C., Becker, L. E., Reynolds, G. P., Bird, E. D., Riederer, P., Jellinger, K., Watanabe, S., et al. (1987) · Synapse · doi:10.1002/syn.890010503 · Cited by 404
Cited by
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
“as compared to healthy age-matched controls using the same PET ligand demonstrated no change in D1 binding in dlPFC, but nevertheless, negative symptoms correlated with the density of D1 binding in right dlPFC (Karlsson et al. 2002).”
BackgroundResultGlutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Neurobiology of Dopamine in Schizophrenia
Guillin, O., Abi‐Dargham, A., & Laruelle, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78001-1 · Cited by 365
“Despite the limited information that this parameter provides to characterize DA function, recent PET imaging studies have described interesting relationships between alterations of D1 receptor availability and cognitive functions in schizophrenia (Abi-Dargham et al. 2002; Karlsson et al. 2002; Okubo et al. 1997).”
BackgroundInfluentialNeuroplasticity of Neocortical Circuits in Schizophrenia
Lewis, D. A., & González-Burgos, G. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301563 · Cited by 365
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
Pathway-Specific Dopamine Abnormalities in Schizophrenia
Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2104 · Cited by 297
Bertolino, A., Caforio, G., Blasi, G., De Candia, M., Latorre, V., Petruzzella, V., Altamura, M., Nappi, G., Papa, S., Callicott, J. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1798 · Cited by 289
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia
Abi-Dargham, A., & Moore, H. (2003) · The Neuroscientist · doi:10.1177/1073858403252674 · Cited by 277
Phenotype of schizophrenia: a review and formulation
Tamminga, C. A., & Holcomb, H. H. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001563 · Cited by 262
Dopamine hypothesis of schizophrenia: Making sense of it all
Toda, M., & Abi-Dargham, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0041-7 · Cited by 235
“The fi rst reported decreased [ 11 C]SCH 23390 binding potential in the PFC [29], and the other reported no change [ 31 ].”
BackgroundThe neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Tauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., Remington, G., Zipursky, R. B., & Kapur, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1620 · Cited by 159
Kessler, R. M., Woodward, N. D., Riccardi, P., Li, R., Ansari, M. S., Anderson, S., Dawant, B., Zald, D., & Meltzer, H. Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.029 · Cited by 136
Woodward, N. D., Cowan, R. L., Park, S., Ansari, M. S., Baldwin, R. M., Li, R., Doop, M., Kessler, R. M., & Zald, D. H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020165 · Cited by 90
Jucaite, A., Forssberg, H., Karlsson, P., Halldin, C., & Farde, L. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.034 · Cited by 67
Self-citationNikolaus, S., Mamlins, E., Hautzel, H., & Müller, H.-W. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0037 · Cited by 35
Metadata
- Authors
- Karlsson, P., Farde, L., Halldin, C., & Sedvall, G.
- Venue
- American Journal of Psychiatry
- Published
- 2002-05-01
- Volume
- 159
- Issue
- 5
- Pages
- 761-767
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2111335060
- Cited by
- 172
- References
- 4
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.